Jimena Gómez Pérez

Dr. Jimena María Gómez Pérez is a leading specialist in Clinical Immunology, currently affiliated with the Hospital Universitario Fundación Jiménez Díaz in Madrid, where she plays a crucial role in clinical and biochemical analysis. Her academic background includes a Bachelor of Medicine degree from the Universidad Autónoma de Madrid, complemented by an Official Doctoral Program in Biomedical Research at the Universidad Complutense de Madrid. Although information on awards is unavailable, her contribution to the field is reflected in her publication in The Lancet, entitled "Hyperimmune immunoglobulin for hospitalized patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomized trial." Furthermore, Dr. Gómez Pérez is an active member of the Sociedad Española de Inmunología, which underscores her commitment to the scientific community and her dedication to immunology research.